Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: IMC-11F8
Biological: IMC-11F8 I.V.

First Posted Date: 2008-12-03

Last Posted Date: 2010-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT00801177

Locations: 🇳🇱
ImClone Investigational Site, Utrecht, Netherlands

A Study in Adult Patients With Major Depressive Disorder

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo
Drug: LY2216684

First Posted Date: 2008-11-21

Last Posted Date: 2018-03-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 495

Registration Number: NCT00795821

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tomsk, Russian Federation

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: IMC-1121B
Biological: 1121B

First Posted Date: 2008-11-19

Last Posted Date: 2013-08-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 37

Registration Number: NCT00793975

Locations: 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States

A Study in the Treatment of Osteoarthritis Knee Pain

Phase 2

Completed

Conditions: Osteoarthritis Knee Pain

Interventions: Drug: Placebo
Drug: LY545694 49 mg
Drug: LY545694 105 mg

First Posted Date: 2008-11-14

Last Posted Date: 2012-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 147

Registration Number: NCT00790790

Locations: 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Targu-Mures, Romania

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo solution and Lifestyle Measures
Drug: LY2189265 and Lifestyle Measures

First Posted Date: 2008-11-14

Last Posted Date: 2014-12-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 167

Registration Number: NCT00791479

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrevieja, Spain

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Other: Best Supportive Care
Drug: Placebo

First Posted Date: 2008-11-11

Last Posted Date: 2018-12-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 939

Registration Number: NCT00789373

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: IMC-1121B
Biological: 1121B

First Posted Date: 2008-11-06

Last Posted Date: 2013-08-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 25

Registration Number: NCT00786383

Locations: 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

Phase 2

Completed

Conditions: Diabetic Neuropathy, Painful

Interventions: Drug: LY545694 49 mg
Drug: LY545694 105 mg
Drug: Placebo
Drug: LY545694 21 mg
Drug: Pregabalin

First Posted Date: 2008-11-05

Last Posted Date: 2012-05-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 273

Registration Number: NCT00785577

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: IMC-A12

First Posted Date: 2008-11-05

Last Posted Date: 2011-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT00785941

Locations: 🇺🇸
ImClone Investigational Site, Nashville, Tennessee, United States

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: IMC-A12

First Posted Date: 2008-11-05

Last Posted Date: 2019-01-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT00785538

Locations: 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy